Mochida Pharmaceutical Co., Ltd.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Mochida Pharmaceutical Co., Ltd.'s yearly results (2023–2026), compared with Healthcare companies in Japan. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ¥100 of reported profit came with ¥-30 of operating cash. Lower than 98% of Healthcare companies in Japan.
- Cash Locked Ratio: For every ¥100 of sales, ¥51 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥41 tied up three years earlier. More money tied up than 89% of Healthcare companies in Japan.
Where ¥100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥-30Over the last 3 years, every ¥100 of reported profit came with ¥-30 of operating cash.
Lower than 98% of Healthcare companies in Japan.
Self-Funding Ratio
-0.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 79% of Healthcare companies in Japan.
Cash Locked Ratio
¥51For every ¥100 of sales, ¥51 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥41 tied up three years earlier.
More money tied up than 89% of Healthcare companies in Japan.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 55% of Healthcare companies in Japan.
Growth Efficiency Ratio
¥9Sales grew 13% in 3 years; of every extra ¥100 of sales, ¥9 became extra profit.
Higher than 60% of Healthcare companies in Japan.
Asset Productivity Ratio
+13% / +15%In 3 years sales changed by +13% while total assets changed by +15%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+18%Cash, after subtracting all debt, equals 18% of its market value (net cash).
Higher than 74% of Healthcare companies in Japan.
Tangible Assets Ratio
99%Of every ¥100 the company owns, ¥99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 77% of Healthcare companies in Japan.
Tangible Net Worth Ratio
99%Of every ¥100 of net worth, ¥99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 80% of Healthcare companies in Japan.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Mochida Pharmaceutical Co., Ltd. owes ¥0.23 for every ¥1 it owns. Net profit rose 39% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
12.5Investors pay ¥12.5 for every ¥1 of Mochida Pharmaceutical Co., Ltd.'s yearly profit, lower than 67% of Healthcare companies in Japan.
P/B ratio
0.80The share price is 0.80 times Mochida Pharmaceutical Co., Ltd.'s book value per share, lower than 85% of Healthcare companies in Japan.
Market cap
¥112.7 BThe total market value of all of Mochida Pharmaceutical Co., Ltd.'s shares at today's price (share price × number of shares), larger than 75% of Healthcare companies in Japan. PosiCap size class: Mini Cap.
Net worth (book value)
¥140.3 BWhat Mochida Pharmaceutical Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
¥3,995Net worth divided by the number of shares. The share price of ¥3,210 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
6.8%Mochida Pharmaceutical Co., Ltd. earned 6.8% on its shareholders' money over the last year, lower than 54% of Healthcare companies in Japan.
Owes vs Owns
0.23×Mochida Pharmaceutical Co., Ltd. owes ¥0.23 for every ¥1 it owns (low), lower than 71% of Healthcare companies in Japan.
Dividend yield
2.62%Mochida Pharmaceutical Co., Ltd. pays 2.62% of its share price as dividends a year, lower than 54% of dividend-paying Healthcare companies in Japan.
Revenue growth
+11%Revenue rose 11% in the year to Mar 2026, and grew 4% a year on average over 3 years.
Profit growth
+39%Net profit rose 39% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Profit margin
6.8%Mochida Pharmaceutical Co., Ltd. keeps ¥7 of every ¥100 of revenue as net profit.
Cash quality
-0.9×Cash from Mochida Pharmaceutical Co., Ltd.'s business was -0.9× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
140.9×Mochida Pharmaceutical Co., Ltd.'s operating profit covered its interest costs 140.9 times in the year to Mar 2026.
Cash vs debt
Net cashMochida Pharmaceutical Co., Ltd. held ¥21.1 B more cash than debt (net cash) at Mar 2026.
Questions
What is Mochida Pharmaceutical Co., Ltd.'s P/E ratio?
Investors pay ¥12.5 for every ¥1 of Mochida Pharmaceutical Co., Ltd.'s yearly profit, lower than 67% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Mochida Pharmaceutical Co., Ltd.: ¥112.7 B ÷ ¥140.3 B (31 Mar 2026) = 0.8.
What is Mochida Pharmaceutical Co., Ltd.'s return on equity?
Mochida Pharmaceutical Co., Ltd. earned 6.8% on its shareholders' money over the last year, lower than 54% of Healthcare companies in Japan.
How much does Mochida Pharmaceutical Co., Ltd. owe compared with what it owns?
Mochida Pharmaceutical Co., Ltd. owes ¥0.23 for every ¥1 it owns (low), lower than 71% of Healthcare companies in Japan.
Does Mochida Pharmaceutical Co., Ltd. pay a dividend?
Yes. Mochida Pharmaceutical Co., Ltd. pays 2.62% of its share price as dividends a year, lower than 54% of dividend-paying Healthcare companies in Japan.
Is Mochida Pharmaceutical Co., Ltd.'s revenue growing?
Revenue rose 11% in the year to Mar 2026, and grew 4% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.